-+ 0.00%
-+ 0.00%
-+ 0.00%

Gene One Life Science unit VGXI extends buyback option on Conroe plant to Dec. 15 for USD 39.9 million

PUBT·09/23/2026 05:32:14
Listen to the news
Gene One Life Science unit VGXI extends buyback option on Conroe plant to Dec. 15 for USD 39.9 million
  • Gene One Life Science’s unit VGXI extended the buyback-option window tied to its Conroe Plant 2 deed-in-lieu financing.
  • New option maturity set for Dec. 15, 2026, from Sept. 1, 2026, extending the deadline by about 3.5 months.
  • Total buyback price set at USD 39.9 million, including amounts for accrued interest, fees, lease costs, holding costs, premium.
  • Payment schedule calls for USD 2 million on Oct. 7, USD 2 million on Oct. 30, balance USD 35.9 million on Dec. 15.
  • Board decision date for the extension agreement: Sept. 23, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gene One Life Science Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260923800336), on September 23, 2026, and is solely responsible for the information contained therein.